

Regulating Digital Health Tools

Understanding the FDA's New Guidances

Table of Contents

Introduction

The FDA's New Mobile App Policies	3
Focus on CDS Software.....	3
Transparency and CDS Software	6
Enforcement Discretion: Regulated v. Unregulated	7
Machine Learning.....	9
Pharma Apps.....	11
Predicting FDA Behavior	15
IMDRF and the FDA's Pilot Precertification Program.....	17
The Precertification Pilot Program	19
Collecting Real-World Data.....	22
Regulatory Underpinnings of CDS Oversight.....	24
Appendices.....	29
A. FDA Guidance: <i>Mobile Medical Applications</i>	
B. FDA Draft Guidance: <i>Clinical and Patient Decision Support Software</i>	
C. FDA Guidance: <i>Medical Device Accessories – Describing Accessories and Classification Pathways</i>	
D. FDA Guidance: <i>General Wellness – Policy for Low Risk Devices</i>	
E. FDA Guidance: <i>Software as a Medical Device (SAMD) – Clinical Evaluation (IMDRF)</i>	
F. FDA Draft Guidance: <i>Multiple Function Device Products – Policy and Considerations</i>	